New Method Boosts Power and Precision of Cancer-Killing Immune Cells

Researchers have found a way to make cancer-killing immune cells more powerful and precise by adding specific signaling components to chimeric antigen receptors (CARs), which boosts the cells’ readiness to attack tumors. Surprisingly, briefly suppressing the cells with a drug before use made them even more effective later. This approach could help create safer, stronger next-generation cancer treatments.

The findings come from a study conducted by scientists at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) in Brazil, who tested new designs of CARs on the NK-92 cell line, a commonly used model for natural killer (NK) cell research. By incorporating signaling domains such as 2B4 and DAP12 into the CAR structure, the researchers enhanced the cells’ activation state, improving their ability to target and destroy tumor cells.

CAR-based therapies have already transformed cancer treatment, especially for blood-related cancers, by engineering a patient’s immune cells to recognize and attack malignancies. While much of the focus has been on CAR-T cells, optimizing CAR-NK cells remains a challenge due to gaps in understanding which internal signaling mechanisms allow these cells to perform at their best. The Brazilian study addresses this gap by identifying how specific costimulatory components influence NK cell activity.

The researchers found that adding 2B4 and DAP12 to the CAR design significantly increased the cells’ readiness to attack tumors. When the engineered NK cells were briefly exposed to a suppressing drug prior to use, their anti-cancer activity was enhanced upon subsequent stimulation — a counterintuitive result suggesting that temporary inhibition may prime the cells for a stronger response.

This dual strategy — enhancing activation through targeted signaling components and improving function via transient suppression — points to a potential pathway for refining immunotherapies. The approach may help overcome limitations such as T-cell exhaustion or insufficient persistence in the tumor microenvironment, which have hindered the effectiveness of some immune-based treatments.

The study was published in Frontiers in Immunology and contributes to ongoing efforts to develop safer, more precise cancer treatments by harnessing the body’s own immune system. Researchers note that while the results are promising, further investigation is needed to determine how these findings translate to clinical applications in human patients.

As immunotherapy continues to evolve, studies like this one highlight the importance of fine-tuning cellular engineering strategies to improve both the potency and safety of immune cell therapies. Future work will likely focus on validating these approaches in preclinical models and eventually in early-stage clinical trials.